Inhibrx Inc

Inhibrx — Investor Presentation (April 2022)

44 slides from Inhibrx's investor presentation, Apr 4, 2022

  1. Slide 1: Outcomes Focused, Innovation Driven

    Outcomes Focused Innovation Driven April 2022

  2. Slide 2: Forward-looking statements

    2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol

  3. Slide 3: Four differentiated clinical programs

    3 Four differentiated clinical programs INBRX-109 Tetravalent DR5 agonist + Single agent activity in chondrosarcoma + Potential rapid path to approval in chondrosarcoma, registration study initiated + Initial combination cohorts with data in 2H 2022: mesothelioma, pancreatic adenocarcinoma, colorect

  4. Slide 4: Why invest in Inhibrx?

    4 Why invest in Inhibrx? Backed by solid institutional investor base with substantial internal ownership Four differentiated clinical programs with value-creating readouts in 2022/2023 KEY FINANCIAL HIGHLIGHTS* 39.0M $152.8M 44.7MRobust emerging pre-clinical pipeline Potential to reach financial sus

  5. Slide 5: Inhibrx at a glance

    5 Inhibrx at a glance + Experienced leadership team + Proven innovation and execution PARTNERSHIPS WITH INDUSTRY LEADERS All platforms and programs developed in-house with strong patent protection Inhibrx’s modular sdAb platform + Ability to precision engineer to specific target biology + Smaller th

  6. Slide 6: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

    INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein AAT Fc

  7. Slide 7: Alpha-1 antitrypsin deficiency (AATD)

    7 Alpha-1 antitrypsin deficiency (AATD) Disease overview + AATD is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT) causing loss of lung function and decreased life expectancy + A small percentage of patients also develop liver disease Current st

  8. Slide 8: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101

    8 Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential advantages of INBRX-101 Potential to extend the dosing interval from weekly to monthly Goal is to maintain patients in the normal serum range of AAT and to normalize the functional activity of AAT Recombinant manufacturi

  9. Slide 9: INBRX-101 - Initial results from Phase 1, Part 1

    9 INBRX-101 - Initial results from Phase 1, Part 1 N=24 Complete N=6 10 mg/kg N=6 40 mg/kg N=6 120 mg/kg N=6 80 mg/kg Single ascending dose escalation (SAD) PART 1 + Favorable safety and tolerability profile with no drug-related SAEs at doses up to and including 120 mg/kg SAD and 80 mg/kg MAD + Dose

  10. Slide 10: INBRX-101 - Initial results from Phase 1, Part 2

    10 Complete Ongoing Completion of Phase 1, Part 2 expected 1H 2022 INBRX-101 - Initial results from Phase 1, Part 2 - 40 mg/kg N=18 * bronchoalveolar lavage N=6 40 mg/kg N=6 80 mg/kg* N=6 120 mg/kg* INBRX-101 Initial Results - 40 mg/kg (Q3W) Initial data from 40 mg/kg predicts a dose of 80-120 mg/kg

  11. Slide 11: AATD therapeutic landscape

    11 THERAPIES Plasma-Derived AAT Aralast Glassia Prolastin-C Zemaira Inhaled AAT Oral Neutrophil Elastase Inhibitor Alvelestat Small Molecule Corrector ZF874 AATD therapeutic landscape Applicable to all patients THERAPIES ARO-AAT DCR-A1AT 15%100% Applicable to ~15% of patients with liver issues

  12. Slide 12: INBRX-101 potential ~$3B annual U.S. revenue

    12 INBRX-101 has the potential to achieve ~$3B in annual U.S. revenue with expected rapid uptake in patients with severe AATD Notes: *Pricing assumption is for modelling purposes only Source: KOL Qualitative Interviews (n=~25); EvaluatePharma, Datamonitor, IQVIA, Fortune Business Insights, Analog an

  13. Slide 13: INBRX-101 potential to shift the treatment paradigm

    13 INBRX-101 has the potential to shift the treatment paradigm, expanding augmentation therapy to a broad group of AATD patients in the U.S. Notes: *Market Revenue for the “Less Severe” dependent on multitude of factors including pricing based on optimal dose in this population; Sources: KOL Intervi

  14. Slide 14: INBRX-109 Tetravalent DR5 Agonist

    INBRX-109 Tetravalent DR5 Agonist

  15. Slide 15: Tetravalent DR5 agonist

    15 Tetravalent DR5 agonist + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells DR5: sdAb DR5: sdAbDR5: sdAb DR5: sdAb 105 kDa Fc: effector function disabled

  16. Slide 16: INBRX-109 is a best-in-class DR5 agonist

    16 INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) INBRX-109 Tetravalent 105 TAS-2661 Tetravalent 60 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 GEN10291,2 Dodecavalent 150 ka (2x mAbs) IGM-8444 Decavalent3 ~950 Dulanermin (recombinant TRAIL) Trivalent 150 Tigatuzumab B

  17. Slide 17: Preliminary Phase 1 data in chondrosarcoma

    17 Best Response 3mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD (+7%) PD (+31%) PD (+16%) Pending ► Pending ► Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

  18. Slide 18: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma

    18 ENDPOINTS Primary: Progression free survival Secondary: Overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc. INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization Conventional chondrosarcoma, Grades 1, 2

  19. Slide 19: Chondrosarcoma patient pool of ~2.5K in the U.S.

    19 Many patients with local disease eventually progress to unresectable or metastatic chondrosarcoma, providing an annual prevalent patient pool of ~2.5K in the U.S. At Diagnosis Recurrence at 10 years Conventional chondorsarcoma Local (~75%) Low grade resectable (~55%) Metastatic (~25%) High grade

  20. Slide 20: INBRX-109 potential ~$1B annual revenue

    20 Based on current trends and lack of approved options, INBRX-109 has the potential to achieve ~$1B in annual revenue with rapid uptake post launch Notes: *Pricing assumption is for modelling purposes only based on analogous market research for oncology products in rare indications; Sources: KOL qu

  21. Slide 21: Phase 1 single agent data in mesothelioma

    21 Best response 3mo 6mo 9mo SD (-24%) * SD (-17%) SD (-12%) PR (-100%) SD (-22%) SD (-20%) SD (-12%) SD (-5%) SD (-2%) SD (+9%) SD (+13%) SD (+16%) SD (+1%) * PD PD PD PD (+25%) PD (+33%) PD (+33%) Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

  22. Slide 22: INBRX-109 on the horizon

    22 Ongoing Ongoing POTENTIAL FUTURE OPPORTUNITIES Solid tumors + IAP antagonists Hematologic tumors + Bcl-2 inhibitors NSCLC + various combo agents Gastric and colon cancer + various combo agents Additional sarcoma indications INBRX-109 on the horizon Combination studies Pancreatic adenocarcinoma 2n

  23. Slide 23: INBRX-106 Hexavalent OX40 Agonist

    INBRX-106 Hexavalent OX40 Agonist

  24. Slide 24: Hexavalent OX40 agonist

    24 Hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells: + Provides co-stimulation to activated T-cells + Reverses regulatory T-cell induced immune suppression + Enhances T-cell functionality + Additional benefit in combination with PD-1 blockade OX40: sdAb OX40: sdAb OX40:

  25. Slide 25: INBRX-106 is a best-in-class OX40 agonist

    25 INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) MOXR-0916 Bi- IgG1 Y Discontinued GSK-3174998 Discontinued BMS-986178 Ph 1 (2016) INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discon

  26. Slide 26: INBRX-106 Phase 1 in combination with Keytruda

    26 Complete PART 3 + Examples of activity: o Two durable PRs > 6 months and treatment ongoing (nasopharyngeal carcinoma and uveal melanoma, both CPI-naïve) o One double-digit reduction in tumor size with duration >4 months (CPI-exposed cutaneous melanoma) + Well-tolerated with mild or moderate immun

  27. Slide 27: INBRX-106 Phase 1 preliminary single agent activity

    27 Complete INBRX-106 Phase 1 preliminary single agent activity Ongoing Dose escalation Dose expansion PART 1 + 4/10 response evaluable NSCLC & melanoma patients with duration of stable disease* greater than 6 months (three CPI- exposed patients and one CPI-naïve uveal melanoma patient) + Longest du

  28. Slide 28: Market opportunity

    28 Market opportunity The figures on this slide represent market research estimates from Evaluate Pharma *Keytruda™ and Opdivo® go off patent in 2028 $14.4 $7.9 $2.9 $2.0 $1.0 $28.2$27.1 $14.2 $7.4 $4.7 $10.1 $63.5 $0 $10 $20 $30 $40 $50 $60 $70 KEYTRUDA* OPDIVO* TECENTRIQ IMFINZI OTHER TOTAL 2020 P

  29. Slide 29: INBRX-105 PD-L1 x 4-1BB Multispecific

    INBRX-105 PD-L1 x 4-1BB Multispecific

  30. Slide 30: PD-L1 x 4-1BB multispecific

    30 PD-L1 x 4-1BB multispecific + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive 4-1BB agonism has achieved anti-tumor respons

  31. Slide 31: INBRX-105 is a potential best-in-class 4-1BB agonist

    31 INBRX-105 is a potential best-in-class 4-1BB agonist CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/a CANDIDATE IGG SUBCLAS

  32. Slide 32: INBRX-105 Phase 1 trial design

    32 PlannedInitiatedOngoingComplete INBRX-105 Phase 1 trial design Single agent: PD-L1+ basket Single agent dose escalation Single agent dose expansion N=80N=32 N=15+N=32 No pre-screening, all-comers + 8/18 (44%) at dose levels ≥ 0.1 mg/kg achieved stable disease + Patients were not pre-screened for

  33. Slide 33: Molecular Targeted Cytokine (MTC) Platform

    Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform

  34. Slide 34: Affinity differential enables directed IL-2 expansion

    34 Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors + Inhibitory receptors + Exhaustion markers Pr

  35. Slide 35: INBRX-121 NKp46 Targeted Detuned IL-2

    INBRX-121 NKp46 Targeted Detuned IL-2

  36. Slide 36: INBRX-121 expands the NK cell population and enhances cytotoxicity

    36 INBRX-121 expands the NK cell population and enhances cytotoxicity + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells + Proprietary IL2-X engineering ensures specific modulation of NK Cells without impacting T-cell subsets (Tcon and Treg) NKp46 sdAb NKp46 sd

  37. Slide 37: INBRX-121 poised to bring NK cells to the forefront of immunotherapy

    37 INBRX-121 INBRX-121 is poised to bring NK cells to the forefront of immunotherapy NK NK NK NK NK NK NK NK NK NK Improved NK Activity Safety with durability Multiple paths forward Single agent Activated NK cells exhibit immediate cytotoxicity Combination therapy Enhances the activity of therapeuti

  38. Slide 38: Expands mouse NK cells and enhances cytotoxic potential

    38 Expands mouse NK cells and enhances their cytotoxic potential 0 2,000 3,000 4,000 5,000 KL RG 1 le ve ls 5,000 10,000 15,000 20,000 Gr an zy m e B le ve ls M ax . f ol d- ch an ge (r el at iv e to v eh ic le ) 0 5 10 20 25 15 NK cells CD8 T cells Tregs CD4+Tcon B cells NK cell cytolytic activityN

  39. Slide 39: Synergizes with approved therapeutic antibodies

    39 Synergizes with approved therapeutic antibodies INBRX-121 synergizes with Rituxan® in a subcutaneous Raji tumor model resulting in complete tumor regression Dosing Days TREATMENT COMPLETE RESPONSES Rituxan® 0/10 INBRX-121 + Rituxan® 9/10 Raji tumor growth 0 42 Time (days) 0 Tu m or Vo lu m e (m m

  40. Slide 40: INBRX-121 safely expands NK cells in non-human primates

    40 INBRX-121 safely expands NK cells in non-human primates 8% 82% 10% 41.5% 51.5% 7% Expands NK cells in a dose-dependent manner (up to 12-fold) that persists for more than 21 days and can be dosed multiple times safely Tolerated at all tested doses (up to 30 mg/kg) with no clinical signs of toxicit

  41. Slide 41: Expands NK cells from lymphoma patients

    41 Expands NK cells from Lymphoma patients NK cells from Lymphoma patients express NKp46 at levels similar or above that of healthy donors Patient NK cells respond to stimulation with INBRX-121 by upregulating pSTAT5 and show an increased proliferative potential - + Healthy Donor 0 20 40 % p ST AT 5

  42. Slide 42: Expands NK cell number while enhancing cytotoxic capacity

    42 Expands the number of NK cells while enhancing their individual cytotoxic capacities INBRX-121 increases NK cell-mediated killing of Raji cells in the presence of a Rituximab sequence analog (Anti-hCD20- hIgG1). Raji cell killing after INBRX-121 pre-incubation Effector: target ratio 0 % Ta rge t

  43. Slide 43: Near term expected clinical milestones

    43 Near term expected clinical milestones 1H 2022 2H 2022 (OX40) / Keytruda initial dose expansion cohort data (AAT) Additional Phase 1 data (PD-L1 x 41BB) Keytruda dose escalation data (PD-L1 x 41BB) Keytruda dose expansion cohort data (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic cancer, a

  44. Slide 44: Contact details

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com

Inhibrx — Investor Presentation (April 2022) on 6ix